Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 8:9:912641.
doi: 10.3389/fmed.2022.912641. eCollection 2022.

Functional Drug Screening in the Era of Precision Medicine

Giulia C Napoli  1 , William D Figg  1 , Cindy H Chau  1
Affiliations
Review

Functional Drug Screening in the Era of Precision Medicine

Giulia C Napoli et al. Front Med (Lausanne). .

Abstract

The focus of precision medicine is providing the right treatment to each unique patient. This scientific movement has incited monumental advances in oncology including the approval of effective, targeted agnostic therapies. Yet, precision oncology has focused largely on genomics in the treatment decision making process, and several recent clinical trials demonstrate that genomics is not the only variable to be considered. Drug screening in three dimensional (3D) models, including patient derived organoids, organs on a chip, xenografts, and 3D-bioprinted models provide a functional medicine perspective and necessary complement to genomic testing. In this review, we discuss the practicality of various 3D drug screening models and each model's ability to capture the patient's tumor microenvironment. We highlight the potential for enhancing precision medicine that personalized functional drug testing holds in combination with genomic testing and emerging mathematical models.

Keywords: chemosensitivity; drug screening; functional medicine; organoid; precision oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Comparison of 3D patient-derived drug screening platforms. Pictogram was created with Biorender.com.
See this image and copyright information in PMC

References

    1. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. (2017) 23:1028–35. 10.1038/nm.4389 - DOI - PubMed
    1. Fojo T. Precision oncology: a strategy we were not ready to deploy. Semin Oncol. (2016) 43:9–12. 10.1053/j.seminoncol.2016.01.005 - DOI - PubMed
    1. FAD. FDA Recognizes Memorial Sloan-Kettering Database of Molecular Tumor Marker Information. Silver Spring, MD: Food and Drug Administration; (2021).
    1. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (Nci-Match). J Clin Oncol. (2020) 38:3883–94. 10.1200/JCO.19.03010 - DOI - PMC - PubMed
    1. Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (Shiva): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. (2015) 16:1324–34. 10.1016/S1470-2045(15)00188-6 - DOI - PubMed

LinkOut - more resources